Tenaya Therapeutics Logo
US87990A1060
TNYA

Tenaya Therapeutics

Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 2,12 € (+606,67 %). Medianen er 1,82 € (+506,67 %).

Køb
  6
Behold
  0
Sælg
  0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Tenaya Therapeutics receives RMAT designation for gene therapy TN-401

    The FDA has granted RMAT designation to Tenaya Therapeutics' AAV9-based gene therapy TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy. The decision is based on interim RIDGE-1 Phase 1b/2 data showing lower rates of premature ventricular contractions and non-sustained ventricular tachycardias. TN-401 already had Fast Track and orphan drug status; the RMAT designation enables expanded interactions with the FDA and may open accelerated approval pathways. Tenaya plans to present additional RIDGE-1 data and an update on regulatory plans for a pivotal trial in Q4 2026. » Mere på de.investing.com


  • Tenaya presents promising gene therapy data and cites liquidity through Q3 2027

    At an investor conference, Tenaya reported positive early efficacy and safety data for its three clinical programs: TN-201 showed sustained improvements in six evaluable patients up to two years after a single dose, TN-401 reduced premature ventricular contractions by a median of 64%, and TN-301 is being readied for Phase II. Management is working on dose selection, regulatory alignment and development plans and expects clarity by the end of 2024. Tenaya reports cash runway through the third quarter of 2027, stressing that this provides time for several clinical and regulatory milestones before additional financing would be needed. » Mere på de.investing.com


  • Tenaya Therapeutics expects regulatory clarity and funding needs in fourth quarter

    At the Canaccord Growth Conference, Tenaya reported positive early safety and efficacy signals for gene therapies TN-201 and TN-401 and the reactivation of the small‑molecule program TN-301. Regulatory decisions on the design of approval‑relevant studies for TN-201 and TN-401, as well as details on TN-301, are expected in the fourth quarter and will determine further capital allocation. The company noted cash of roughly $78 million, expected to last into the third quarter of 2027, but stressed that additional financing will be required for the planned registration and Phase II studies. » Mere på de.investing.com


  • Tenaya reports positive interim results for gene therapy TN-401 in ARVC

    Tenaya presented interim results from the phase 1b/2 RIDGE‑1 study: in six patients a single infusion of TN‑401 led to a mean reduction in premature ventricular contractions of about 60–67% and the treatment was reported to be well tolerated. Biopsies showed presence of TN‑401 DNA and stable to slightly improved PKP2 protein levels; common adverse events were transient increases in troponin or transaminases. The EMA has granted TN‑401 PRIME status. Financial analyses highlight stronger liquidity than debt but note negative free cash flow, while analyst price targets range between $2 and $8. » Mere på de.investing.com


  • Tenaya Therapeutics receives Nasdaq warning over minimum share price and boosts stock plan

    Tenaya Therapeutics received a warning from Nasdaq because the closing price was below $1.00 for 30 consecutive trading days; the company has until July 27, 2026 to raise the price to $1.00 or more for at least ten trading days. The board increased the shares reserved for the 2024 Inducement Equity Incentive Plan by 2,161,000 to a total of 3,361,000 shares. At the same time, Tenaya plans a $60 million capital raise (50 million units at $1.20) and announced that the FDA lifted the clinical hold on the MyPEAK-1 study of TN-201; interim results from the Phase 1b RIDGE-1 study were also released, after which analysts lowered their price targets but maintained buy ratings. » Mere på de.investing.com

I 2022 har Tenaya Therapeutics allerede udloddet 1,13 € i udbytte. Den seneste udlodning fandt sted i marts 2022.

Virksomhedstal

I det seneste kvartal havde Tenaya Therapeutics en omsætning på 1,5 mio. € og et nettoresultat på -16,72 mio. €
(EUR) september 2026
YoY
Omsætning 1,5 mio. -
Bruttofortjeneste 1,5 mio. -
Nettoresultat -16,72 mio. 3,23 %
EBITDA -16,26 mio. 3,67 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
72,41 mio. €
Antal aktier
227,93 mio.
Højeste/laveste i 52 uger
1,33 € - 0,27 €
Udbytte Nej
Beta
2,88
P/E (PE Ratio)
-0,71
PEG (PEG Ratio)
-0,02
K/I (PB Ratio)
1,45
P/S (PS Ratio)
26,25

Virksomhedsprofil

Tenaya Therapeutics, Inc., et biotekselskab, opdager, udvikler og leverer terapier mod hjertesygdomme i USA. Virksomheden udvikler sine produkter gennem platforme inden for cellulær regenerering, genterapi og præcisionsmedicin. Selskabet udvikler TN-201, en genterapi baseret på adeno-associeret virus (AAV), som skal adressere genetisk hypertrofisk kardiomyopati (gHCM) forårsaget af haploinsufficiente mutationer i genet for myosinbindende protein C3 (MYBPC3); og TN-301, en small molecule-hæmmer af histondeacetylase 6 (HDAC6i) til anvendelse ved hjertesvigt med bevaret ejektionsfraktion (HFpEF) og genetisk dilateret kardiomyopati (gDCM). Selskabet udvikler desuden TN-401, en AAV-baseret genterapi, der adresserer genetisk arytmogen højre ventrikulær kardiomyopati (gARVC) forårsaget af mutationer i genet for plakophilin 2 (PKP2); en AAV-baseret genterapi designet til at levere dwarf open reading frame (DWORF)-genet til hjertet ved DCM; og Reprogramming-programmet, en AAV-baseret tilgang til kardial regenerering for at erstatte hjerteceller tabt hos patienter med hjertesvigt efter tidligere myokardieinfarkt. Virksomheden blev stiftet i 2016 og har hovedsæde i South San Francisco, Californien.

Navn
Tenaya Therapeutics
CEO
Faraz Ali
Hjemsted South San Francisco, ca
USA
Websted
Sektor
Sundhed
Branche
Lægemidler
Børsnotering
30.07.2021
Medarbejdere 70

Tickersymboler

Børs Symbol
NASDAQ
TNYA
🍪

Parqet  bruger cookies. Læs mere